ING Groep NV Increases Position in Eli Lilly and Company (NYSE:LLY)

ING Groep NV lifted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 2,395.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 107,336 shares of the company's stock after buying an additional 103,034 shares during the period. ING Groep NV's holdings in Eli Lilly and Company were worth $82,863,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of LLY. AMF Tjanstepension AB lifted its stake in shares of Eli Lilly and Company by 113.7% in the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company's stock worth $293,964,000 after buying an additional 176,552 shares in the last quarter. Values Added Financial LLC lifted its stake in shares of Eli Lilly and Company by 4.9% in the third quarter. Values Added Financial LLC now owns 366 shares of the company's stock worth $324,000 after buying an additional 17 shares in the last quarter. GAM Holding AG lifted its stake in shares of Eli Lilly and Company by 55.3% in the third quarter. GAM Holding AG now owns 29,978 shares of the company's stock worth $26,559,000 after buying an additional 10,677 shares in the last quarter. Liberty Capital Management Inc. lifted its stake in shares of Eli Lilly and Company by 5.7% in the third quarter. Liberty Capital Management Inc. now owns 2,150 shares of the company's stock worth $1,905,000 after buying an additional 115 shares in the last quarter. Finally, Global X Japan Co. Ltd. raised its stake in Eli Lilly and Company by 10.6% during the third quarter. Global X Japan Co. Ltd. now owns 2,614 shares of the company's stock worth $2,316,000 after purchasing an additional 251 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 0.1 %

Shares of LLY stock traded up $1.00 during trading on Friday, reaching $874.12. The company's stock had a trading volume of 3,937,537 shares, compared to its average volume of 3,765,032. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The company has a market capitalization of $829.82 billion, a price-to-earnings ratio of 74.65, a P/E/G ratio of 1.39 and a beta of 0.42. The stock's 50-day moving average price is $799.63 and its 200 day moving average price is $846.07. Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its board has approved a stock repurchase program on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.69%. The ex-dividend date is Friday, February 14th. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.30. Eli Lilly and Company's payout ratio is 51.24%.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Wolfe Research assumed coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They set an "outperform" rating and a $1,000.00 target price on the stock. Barclays reduced their target price on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating on the stock in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating on the stock in a research note on Monday, November 4th. Finally, Citigroup dropped their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average target price of $997.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.